BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 8560639)

  • 1. [New antidepressive agents].
    LaBranche S
    Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients].
    Montejo AI; Llorca G; Izquierdo JA; Ledesma A; Bousoño M; Calcedo A; Carrasco JL; Daniel E; de Dios A; de la Gándara J; Derecho J; Franco M; Gómez MJ; Macías JA; Martín T; Pérez V; Sánchez JM; Sánchez S; Vicens E
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(6):311-21. PubMed ID: 9054202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective serotonin reuptake inhibitors and mammary pathologies].
    Shchepotin IB; Zotov AS; Dobzhenko MN
    Vopr Onkol; 2010; 56(4):393-7. PubMed ID: 20968014
    [No Abstract]   [Full Text] [Related]  

  • 4. [Secondary dermatologic effects of serotonin reuptake inhibitor antidepressants: hypothesis of cross-reacting allergy. Apropos of 2 cases].
    Beauquier B; Fahs H
    Encephale; 1998; 24(1):62-4. PubMed ID: 9559306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of SSRI response.
    Salzman C
    Harv Rev Psychiatry; 1996; 4(4):215-7. PubMed ID: 9384996
    [No Abstract]   [Full Text] [Related]  

  • 6. Reassessment of nefazodone.
    Bryant SG
    Am J Health Syst Pharm; 1996 Oct; 53(19):2339-40, 2343. PubMed ID: 8893078
    [No Abstract]   [Full Text] [Related]  

  • 7. Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence.
    Sprenger D
    J Clin Psychopharmacol; 1997 Oct; 17(5):425-6. PubMed ID: 9315996
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of fetal anomalies with exposure to selective serotonin reuptake inhibitors.
    Grush LR
    JAMA; 1998 Jun; 279(23):1873. PubMed ID: 9634252
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
    Preskorn SH; Alderman J; Chung M; Harrison W; Messig M; Harris S
    J Clin Psychopharmacol; 1994 Apr; 14(2):90-8. PubMed ID: 8195463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
    Dingemanse J; Wallnöfer A; Gieschke R; Guentert T; Amrein R
    Clin Pharmacol Ther; 1998 Apr; 63(4):403-13. PubMed ID: 9585794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
    Preskorn SH
    J Clin Psychiatry; 1995; 56 Suppl 6():12-21. PubMed ID: 7649968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
    Redrobe JP; Bourin M
    Psychopharmacology (Berl); 1998 Jul; 138(2):198-206. PubMed ID: 9718290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
    Montejo-González AL; Llorca G; Izquierdo JA; Ledesma A; Bousoño M; Calcedo A; Carrasco JL; Ciudad J; Daniel E; De la Gandara J; Derecho J; Franco M; Gomez MJ; Macias JA; Martin T; Perez V; Sanchez JM; Sanchez S; Vicens E
    J Sex Marital Ther; 1997; 23(3):176-94. PubMed ID: 9292833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal syndromes after paroxetine and sertraline discontinuation.
    Fava GA; Grandi S
    J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
    [No Abstract]   [Full Text] [Related]  

  • 16. Dystonia associated with trazodone and sertraline.
    Lewis CF; DeQuardo JR; Tandon R
    J Clin Psychopharmacol; 1997 Feb; 17(1):64-5. PubMed ID: 9004068
    [No Abstract]   [Full Text] [Related]  

  • 17. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
    Zajecka J; Tracy KA; Mitchell S
    J Clin Psychiatry; 1997 Jul; 58(7):291-7. PubMed ID: 9269249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant use during pregnancy. FPIN’s clinical inquiries.
    Patel BN; Beste J; Blackwell JC
    Am Fam Physician; 2011 May; 83(10):1211-5. PubMed ID: 21568258
    [No Abstract]   [Full Text] [Related]  

  • 19. Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
    Sánchez C; Hyttel J
    Eur J Pharmacol; 1994 Nov; 264(3):241-7. PubMed ID: 7698161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paroxetine (paxil): use in clinical practice].
    Litvintsev SV; Reznik AM; Arbuzov AL; Mironychev GN
    Voen Med Zh; 2002 Jan; 323(1):35-9. PubMed ID: 11881199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.